Phase I/II study of lenvatinib (E7080), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC): Phase I results

被引：3
|
作者：
Mitsunaga, Shuichi
Ikeda, Masafumi
Ueno, Hideki
Nakachi, Kohei
Morizane, Chigusa
Kondo, Shunsuke
Shimizu, Satoshi
Kojima, Yasushi
Suzuki, Takuya
Tamai, Toshiyuki
O'Brien, James P.
Okusaka, Takuji
机构：
[1] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[2] Natl Canc Ctr, Tokyo, Japan
[3] Natl Ctr Global Hlth & Med, Tokyo, Japan
[4] Eisai, Tokyo, Japan
[5] Eisai, Woodcliff Lake, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 04期
关键词：
D O I：
10.1200/jco.2013.31.4_suppl.231
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
231
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase I study of bavituximab and sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Yopp, Adam
    Arriega, Yuii
    Singal, Amit
    Mansour, John
    Bach, Glen
    Thorpe, Phillip
    CANCER RESEARCH, 2012, 72
  • [32] A phase II study of the multitargeted kinase inhibitor lenvatinib in patients with advanced BRAF wild-type melanoma
    O'Day, Steven
    Gonzalez, Rene
    Kim, Kevin
    Chmielowski, Bartosz
    Kefford, Richard
    Long, Georgina
    Loquai, Carmen
    Cowey, Charles Lance
    Hauschild, Axel
    Hainsworth, John D.
    Hersey, Peter
    Boyle, Frances
    Evans, T. R. Jeffry
    Hamid, Omid
    Meneses, Nicole
    Andresen, Corina
    Ren, Min
    O'Brien, James P.
    Flaherty, Keith
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [33] Phase I study of tramatinib combined with sorafenib in patients (pts) with advanced hepatocellular cancer (HCC).
    Wang, Emilie
    Kim, Dae Won
    Mahipal, Amit
    Chen, Dung-Tsa
    Cao, Biwei
    Masawi, Fadzai
    Kim, Richard D.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [34] PHASE I STUDY OF E7080, A MULTI-TARGETED TYROSINE KINASE INHIBITOR, IN COMBINATION WITH CARBOPLATIN PLUS PACLITAXEL IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Nishio, Makoto
    Horiike, Atsushi
    Horai, Takeshi
    Takahashi, Toshiaki
    Murakami, Haruyasu
    Yamamoto, Nobuyuki
    Yusa, Wataru
    Tamura, Tomohide
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1207 - S1208
  • [35] Phase I dose escalation study of E7080, a novel anti-angiogenic multikinase inhibitor, in Japanese patients with advanced solid tumors
    Yamada, K.
    Fujiwara, Y.
    Yamamoto, N.
    Yamada, Y.
    Suzuki, S.
    Kobayashi, N.
    Koizumi, F.
    Nishio, K.
    Tamura, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [36] Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma
    Hong, David S.
    Kurzrock, Razelle
    Falchook, Gerald S.
    Andresen, Corina
    Kwak, Jennifer
    Ren, Min
    Xu, Lucy
    George, Goldy C.
    Kim, Kevin B.
    Nguyen, Ly M.
    O'Brien, James P.
    Nemunaitis, John
    ONCOTARGET, 2015, 6 (40) : 43127 - 43134
  • [37] A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors
    Molife, L. Rhoda
    Dean, Emma Jane
    Blanco-Codesido, Montserrat
    Krebs, Matthew G.
    Brunetto, Andre T.
    Greystoke, Alastair Peter
    Daniele, Gennaro
    Lee, Lucy
    Kuznetsov, Galina
    Myint, Khin Than
    Wood, Karen
    de las Heras, Begona
    Ranson, Malcolm Richard
    CLINICAL CANCER RESEARCH, 2014, 20 (24) : 6284 - 6294
  • [38] Phase I study of everolimus in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).
    Finn, R. S.
    Poon, R. T. P.
    Yau, T.
    Klumpen, H.
    Chen, L.
    Kang, Y.
    Kim, T.
    Gomez-Martin, C.
    Rodriguez-Lope, C.
    Kunz, T.
    Paquet, T.
    Asubonteng, K.
    Winkler, R. E.
    Anak, O.
    Sellami, D. B.
    Bruix, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [39] Assessment of predictive biological markers with an oral angiogenic receptor tyrosine kinase (RTK) inhibitor, TSU-68, in the Phase I/II study for advanced hepatocellular carcinoma (HCC)
    Okusaka, T.
    Kanai, F.
    Ikeda, M.
    Morizane, C.
    Yoshida, H.
    Tateishi, R.
    Shiina, S.
    Kondo, Y.
    Tagawa, K.
    Omata, M.
    EJC SUPPLEMENTS, 2008, 6 (12): : 17 - 17
  • [40] Final results of a multicenter phase II study of irinotecan (CPT-11) in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Boige, V
    Taieb, J
    Hebbar, M
    Magherini, E
    Mignard, D
    Debaere, T
    Hannoun, L
    Tigaud, JM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 358S - 358S
12345